Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03793868 · ClinicalTrials.gov registry record · Early Phase 1
Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis
A Early Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03793868: Completed Early Phase 1 study of Amyotrophic Lateral Sclerosis, sponsored by Mayo Clinic.
NCT03793868 is a Early Phase 1 study of Amyotrophic Lateral Sclerosis that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03793868, a Early Phase 1 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate if transcranial magnetic stimulation can be used as a biomarker in Amyotrophic Lateral sclerosis (ALS).
Primary Outcome
Transcranial Magnetic stimulation motor threshold change from baseline
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Perampanel
Study Locations (1)
Florida
- Mayo Clinic - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-12-04 |
| Est. Completion | 2020-09-01 |
| Phase | Early Phase 1 |
What the finished NCT03793868 record still lists
NCT03793868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03793868 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03793868 about?
NCT03793868 is a clinical study titled "Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis". To evaluate if transcranial magnetic stimulation can be used as a biomarker in Amyotrophic Lateral sclerosis (ALS).
What is the current status of trial NCT03793868?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2018-12-04. Estimated completion is 2020-09-01.
What conditions does trial NCT03793868 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT03793868?
The interventions under investigation include: Placebo (OTHER), Perampanel (DRUG).
Who is sponsoring clinical trial NCT03793868?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03793868 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03793868's enrollment target sits among peer trials
22 75th of 102 higher than 27 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Early Phase 1
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
-
Assessing Perceptual Effects of Interactive Tasks
RECRUITING · NA
-
PREVENT ALL ALS Study
RECRUITING
-
Spinal Cord Associative Plasticity for ALS
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI